Velocity profiles and shear strain rate variability in the USP Dissolution Testing Apparatus 2 at different impeller agitation speeds

Otto H. York Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
International Journal of Pharmaceutics (Impact Factor: 3.65). 09/2010; 403(1-2):1-14. DOI: 10.1016/j.ijpharm.2010.09.022
Source: PubMed


The fluid velocity profiles at different locations inside a standard USP Dissolution Testing Apparatus 2 were experimentally obtained via Laser Doppler Velocimetry (LDV) at three impeller agitations speeds, namely 50rpm, 75rpm and 100rpm. The experimental results were compared with the predictions obtained with Computational Fluid Dynamics (CFD) where the κ-ω model with low Reynolds number correction was used to account for turbulence effects. In general, good agreement was found between the experimental LDV velocity measurements and the CFD simulation predictions. The non-dimensional tangential, axial and radial velocity profiles (scaled with the impeller tip speed) and the flow pattern were found to be nearly independent of the agitation speed in most regions of the vessel, implying that increasing the agitation speed generally produced a corresponding increase in the local values of the velocity. However, the velocity profiles and flow pattern in the inner core region just below the impeller, where the dissolving tablet is usually located, were found to be much less sensitive to agitation speed. In this region, the axial and radial velocities were especially low and were not significantly affected by agitation increases. This inner core region at the center of the vessel bottom persisted irrespective of agitation intensity. The CFD predictions also indicated that increasing the agitation speed resulted in a higher shear strain rate distribution along the vessel bottom, although the strain rate was always very low at the center of the vessel bottom, even when the agitation speed was increased.

Download full-text


Available from: Piero M. Armenante, Oct 07, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Agitation of small amounts of liquid is performed routinely in biopharmaceutical process, formulation, and packaging development. Protein degradation commonly results from agitation, but the specific stress responsible or degradation mechanism is usually not well understood. Characterization of the agitation stress methods is critical to identifying protein degradation mechanisms or specific sensitivities. In this study, computational fluid dynamics (CFD) was used to model agitation of 1 mL of fluid by four types of common laboratory agitation instruments, including a rotator, orbital shaker, magnetic stirrer and vortex mixer. Fluid stresses in the bulk liquid and near interfaces were identified, quantified and compared. The vortex mixer provides the most intense stresses overall, while the stir bar system presented locally intense shear proximal to the hydrophobic stir bar surface. The rotator provides gentler fluid stresses, but the air-water interfacial area and surface stresses are relatively high given its low rotational frequency. The orbital shaker provides intermediate-level stresses but with the advantage of a large stable platform for consistent vial-to-vial homogeneity. Selection of experimental agitation methods with targeted types and intensities of stresses can facilitate better understanding of protein degradation mechanisms and predictability for "real world" applications.
    International Journal of Pharmaceutics 12/2011; 423(2):264-80. DOI:10.1016/j.ijpharm.2011.11.044 · 3.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amoxicillin clavulanate potassium is a broad spectrum antibiotic used in the management of most bacterial infections. The innovator brand, Augmentin, is expensive, hence the need to substitute them with much cheaper generic brands. This brings about the question of bioequivalency, an essential biopharmaceutic factor that provides option for generic substitution especially in underdeveloped countries such as ours. A study on quality assessment of six generic brands in comparison with the innovator brand was carried to ascertain the quality of the generic brands that are available in Nigerian drug market. Assessment of their bioequivalence was done vis-a-vis the evaluation of physicochemical characteristics such as uniformity of weight, friability, hardness, disintegration, dissolution rate and assay of the brands, using both official and non-official methods. All the brands studied complied with the official specifications on uniformity of weight and friability but the brands AC-2 and AC-7 failed the disintegration time test. Brand AC-7 exhibited a very high crushing strength which consequently affected it's dissolution rate negatively and did not comply with USP specification on dissolution. Out of the six generic brands tested, five of them were considered bioequivalent with the innovator brand with the exception of brand AC-7. Any reported case of therapeutic failure concerning the brands that complied with specification most likely, might be related to bad patient compliance, physiological and pharmacokinetic conditions relating to the patients using the drug and inadequate advice to patients on the part of the healthcare professionals.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously shown that a novel microtubule-modulating noscapinoid, EM011 (9-Br-Nos), displays potent anticancer activity by inhibition of cellular proliferation and induction of apoptosis in prostate cancer cells and preclinical mice models. However, physicochemical and cellular barriers encumber the development of viable formulations for future clinical translation. To circumvent these limitations, we have synthesized EM011-cyclodextrin inclusion complexes to improve solubility and enhance therapeutic index of EM011. Phase solubility analysis indicated that EM011 formed a 1:1 stoichiometric complex with β-CD and methyl-β-CD, with a stability constant (K(c)) of 2.42 × 10(-3) M and 4.85 × 10(-3) M, respectively. Fourier transform infrared spectroscopy suggested the penetrance of either a O-CH(2) or OCH(3)-C(6)H(4)-OCH(3) moiety of EM011 in the β-CD or methyl-β-CD cavity. In addition, multifarious techniques, namely, differential scanning calorimetry, powder X-ray diffraction, scanning electron microscopy, NMR spectroscopy, and computational studies validated the cage complex of EM011 with β-CD and methyl-β-CD. Moreover, rotating frame overhauser enhancement spectroscopy showed that the H(a) proton of the OCH(3)-C(6)H(4)-OCH(3) moiety was in close proximity with H3 proton of the β-CD or methyl-β-CD cavity. Furthermore, we found that the solubility of EM011 in phosphate buffer saline (pH 7.4) was enhanced by ~11 fold and ~21 fold upon complexation with β-CD and methyl-β-CD, respectively. The enhanced dissolution of the drug CD-complexes in aqueous phase remarkably decreased their IC(50) to 28.5 μM (9-Br-Nos-β-CD) and 12.5 μM (9-Br-Nos-methyl-β-CD) in PC-3 cells compared to free EM011 (~200 μM). This is the first report to demonstrate the novel construction of cylcodextrin-based nanosupramolecular vehicles for enhanced delivery of EM011 that warrants in vivo evaluation for the superior management of prostate cancer.
    Molecular Pharmaceutics 04/2012; 9(5):1470-80. DOI:10.1021/mp300063v · 4.38 Impact Factor
Show more